Application of a neutralising antibody against VNN1 reduced internalisation of EVs and the effects on HSCs, suggesting a vital role in the shuttling of miR-128-3p in NAFLD. This evidence concerns the gene VNN1 and metabolic dysfunction-associated steatotic liver disease.